Keystone BioInsights

Dave Hauser is the founder of Keystone BioInsights. He is a drug discovery scientist and program leader with nearly 20 years of experience spanning academic and federal research, biotechnology startups, and mid-sized biopharma. His work has included therapeutic antibodies, neuroscience, biomarkers, phenotypic screening, and multi-omics.

At the National Institutes of Health, Dave worked in the Laboratory of Neurogenetics on proteomic and RNA-seq studies of Parkinson's disease models. He combined hands-on experimental biology with custom analysis of large datasets and contributed to one of the earliest published RNA-seq studies of the mouse brain.

At Versapeutics, Dave led therapeutic antibody programs for Alzheimer's disease and spinal cord injury and led the development of the first patent application for the company's RYK antibody program. He was an architect of the company's SBIR strategy and was awarded the company's first grant prior to departing. After his departure, the company continued to raise SBIR funding totaling more than $6.5 million to advance the RYK antibody project. His work on the RYK patent sparked an interest in the scientific information embedded in antibody patents and the possibility of organizing it systematically, an idea that eventually became the foundation for ARCH.

At Neurocrine Biosciences, Dave led cross-functional small-molecule and therapeutic antibody programs in neurology while developing cell-based pharmacology models to evaluate both modalities. He integrated biomarker and multi-omics evidence into indication selection and program strategy, built the company's first RNA-seq database, and led its first high-throughput imaging-based phenotypic screen.

Across these roles, Dave repeatedly saw how difficult it was to turn scattered scientific information into a clear basis for drug discovery decisions. That experience shaped the approach he is now building at Keystone BioInsights.

Dave received his PhD in Neuroscience from Brown University.

Mark Wilson is Professor and Associate Head of the Department of Biochemistry at the University of Nebraska-Lincoln, where his laboratory uses structural biology to study enzyme catalysis, redox biochemistry, and protein regulation.

Mark is an expert in cysteine reactivity. His laboratory has developed structurally grounded methods for modulating cysteine reactivity by engineering amino acids that interact directly with the cysteine environment. His research also advances time-resolved structural methods at synchrotrons and X-ray free-electron lasers.

Mark serves as Editor-in-Chief of Structural Dynamics and has published nearly 100 peer-reviewed articles.

Mark received his PhD in Molecular Biophysics and Biochemistry from Yale University.

Allissa Dillman is a computational neuroscientist and the founder and CEO of BioData Sage. Her work spans transcriptomics, RNA biology, bioinformatics, and the development of practical biomedical data-science workflows.

At the National Institutes of Health, Allissa conducted RNA-seq studies of gene expression, splicing, and RNA editing in brain tissue. She later led workforce development and community engagement for the NIH Office of Data Science Strategy.

Allissa has designed and taught advanced RNA-seq and next-generation sequencing programs, led collaborative biomedical codeathons, and developed public resources that help researchers use data science, open science, and cloud computing.

Allissa received her PhD in Neuroscience from Karolinska Institutet.

Tracy Charlton is an antibody discovery and protein engineering scientist with more than three decades across academia, GNF/Novartis, and AlivaMab Discovery Services.

During 15 years at GNF/Novartis, Tracy led antibody programs in oncology, immunology, and metabolic disease, advancing two projects to IND. She established its mRNA immunization platform and developed campaigns against challenging targets, including GPCRs, using hybridoma technology, phage display, next-generation sequencing, and humanization.

At AlivaMab, Tracy led up to 14 concurrent programs. She designed high-throughput functional screens using the AlivaMab Mouse and helped establish NGS-enabled discovery and bispecific-antibody platforms.

Tracy received her PhD in Genetics, Cell Biology, Molecular Biology and Biochemistry from the University of British Columbia.